Solas Capital Management LLC bought a new position in Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,393,328 shares of the company's stock, valued at approximately $8,096,000. Alpha Cognition accounts for 5.4% of Solas Capital Management LLC's investment portfolio, making the stock its 9th largest holding. Solas Capital Management LLC owned about 8.70% of Alpha Cognition at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. National Bank of Canada FI bought a new position in Alpha Cognition in the fourth quarter valued at approximately $69,000. MYDA Advisors LLC bought a new position in shares of Alpha Cognition in the 4th quarter valued at about $589,000. Aristides Capital LLC acquired a new position in shares of Alpha Cognition during the 4th quarter worth about $1,178,000. ADAR1 Capital Management LLC acquired a new stake in shares of Alpha Cognition in the fourth quarter valued at approximately $1,204,000. Finally, Rosalind Advisors Inc. acquired a new position in shares of Alpha Cognition in the fourth quarter valued at $1,489,000.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on ACOG. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Alpha Cognition in a research note on Monday, March 31st. Raymond James upgraded Alpha Cognition to a "moderate buy" rating in a research report on Tuesday, March 25th.
Read Our Latest Stock Analysis on ACOG
Alpha Cognition Stock Performance
Shares of ACOG stock traded up $0.29 during mid-day trading on Thursday, reaching $5.81. 25,865 shares of the stock traded hands, compared to its average volume of 78,321. The business has a fifty day moving average price of $5.11. Alpha Cognition, Inc. has a 1-year low of $3.75 and a 1-year high of $7.00. The stock has a market capitalization of $93.08 million, a P/E ratio of -2.27 and a beta of 2.50.
Alpha Cognition (NASDAQ:ACOG - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.03).
About Alpha Cognition
(
Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Featured Articles
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
